Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose VELDONA® interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's products include VELDONA® clinical-stage human therapeutics, VELDONA® Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. The lead POCT candidate, Ainos Flora, is intended to be a telehealth-friendly POCT for women's health and certain common sexually transmitted infections ("STIs"). To learn more, visit https://www.ainos.com.
Company profile
Ticker
AIMD, AIMDW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMARILLO BIOSCIENCES INC
SEC CIK
Corporate docs
IRS number
751974352
AIMD stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
17 Apr 24
S-1
IPO registration
8 Apr 24
8-K
Departure of Directors or Certain Officers
19 Mar 24
8-K
Departure of Directors or Certain Officers
15 Mar 24
8-K
Ainos Reports Full Year 2023 Financial Results
8 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation
5 Feb 24
8-K
Ainos Announces $1.75 Million Follow On Funding
25 Jan 24
8-K
Entry into a Material Definitive Agreement
12 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.37 mm | 2.37 mm | 2.37 mm | 2.37 mm | 2.37 mm | 2.37 mm |
Cash burn (monthly) | (no burn) | 3.85 k | 991.95 k | 831.05 k | 247.77 k | 326.86 k |
Cash used (since last report) | n/a | 25.69 k | 6.62 mm | 5.55 mm | 1.65 mm | 2.18 mm |
Cash remaining | n/a | 2.35 mm | -4.25 mm | -3.18 mm | 716.80 k | 188.77 k |
Runway (months of cash) | n/a | 609.4 | -4.3 | -3.8 | 2.9 | 0.6 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 6 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 211.80 mm |
Total shares | 94.15 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ainos | 93.72 mm | $42.17 mm |
CVI | 82.50 k | $23.68 mm |
Walleye Capital | 65.82 k | $18.89 mm |
Anson Funds Management | 50.00 k | $34.01 mm |
Ayrton Capital | 50.00 k | $14.35 mm |
Hudson Bay Capital Management | 37.90 k | $9.85 mm |
Citadel Advisors | 30.84 k | $8.02 mm |
Warberg Asset Management | 30.30 k | $8.70 mm |
STT State Street | 30.20 k | $20.54 mm |
Boothbay Fund Management | 25.00 k | $17.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 24 | yao-chung chiang | Common Stock | Grant | Acquire A | No | No | 0.94 | 1,466 | 1.38 k | 54,932 |
31 Jan 24 | yao-chung chiang | RSU Common Stock | Conversion | Dispose C | No | No | 0 | 1,466 | 0.00 | 1,466 |
31 Jan 24 | chung-yi tsai | Common Stock | Grant | Acquire A | No | No | 0.94 | 1,466 | 1.38 k | 52,932 |
31 Jan 24 | chung-yi tsai | RSU Common Stock | Conversion | Dispose C | No | No | 0 | 1,466 | 0.00 | 1,466 |
31 Jan 24 | Pao-sheng Wei | Common Stock | Grant | Acquire A | No | No | 0.94 | 1,466 | 1.38 k | 52,932 |
31 Jan 24 | Pao-sheng Wei | RSU Common Stock | Conversion | Dispose C | No | No | 0 | 1,466 | 0.00 | 1,466 |
31 Jan 24 | wen-han chang | Common Stock | Grant | Acquire A | No | No | 0.94 | 1,466 | 1.38 k | 106,265 |
31 Jan 24 | wen-han chang | RSU Common Stock | Conversion | Dispose C | No | No | 0 | 1,466 | 0.00 | 1,466 |
News
12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Mar 24
Ainos FY23 EPS $(3.36) Vs $(5.14) YoY; Revenue $122,112 Vs $3.52M YoY
8 Mar 24
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
8 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
8 Mar 24
Nasdaq Gains Over 50 Points; US Economy Adds 275,000 Jobs In February
8 Mar 24
Press releases
Ainos Reports Full Year 2023 Financial Results
8 Mar 24
Thinking about buying stock in Senseonics Holdings, Ainos, Marpai, Rush Street Interactive, or Evgo?
8 Mar 24
Thinking about buying stock in MMTec, Ainos, Jumia Technologies, Akero Therapeutics, or BioVie?
4 Mar 24
Thinking about buying stock in SoundHound AI, Macy's, Ainos, Helius Medical Technologies, or Renalytix?
4 Mar 24
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
5 Feb 24